Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian White

Neurological Surgery Indianapolis, IN Medical Doctor

NPI 1205101896 CMS profile 326189

1801 N Senate Blvd, Suite 535, Indianapolis, IN 46202

Open in the dashboard

General payments

$41,552

228 records reported · program years 2019–2025

Research payments

$154,301

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ian White of Indianapolis, IN is reported in the CMS Open Payments database as having received $41,552 across 228 general payments and $154,301 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,838 17
2024 General $1,246 11
2023 General $11,281 27
2023 Research $74,067 2
2022 General $7,281 13
2022 Research $80,234 3
2021 General $7,741 22
2020 General $4,081 43
2019 General $7,085 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian White
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Ian White were reported at $2,838. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Ian White Neurological Surgery median Middle half National median
2019 $7,085 $582 $138–$3,006 $163
2020 $4,081 $294 $76–$2,174 $114
2021 $7,741 $387 $105–$2,432 $132
2022 $7,281 $542 $139–$2,989 $149
2023 $11,281 $534 $145–$2,697 $160
2024 $1,246 $574 $155–$3,046 $164
2025 $2,838 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $25,644 57 payments
  2. Medtronic USA, Inc. $7,645 73 payments
  3. Globus Medical, Inc. $2,919 12 payments
  4. Stryker Corporation $2,197 41 payments
  5. Abbott Laboratories $723 7 payments
  6. Kuros Biosciences USA, Inc $706 4 payments
  7. Orthofix Medical, Inc. $295 2 payments
  8. Arteriocyte Medical Systems, Inc. $171 2 payments
  9. Relievant Medsystems, Inc. $166 2 payments
  10. Boston Scientific Corporation $144 1 payment
  11. Other $943 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,250 7 payments
  2. Food and Beverage $14,015 203 payments
  3. Travel and Lodging $5,087 17 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,200 1 payment
Products named General payments · program years 2019–2025
  1. GRAFTONAND GRAFTON PLUSDEMINERALIZED BONE MATRIX (DBM) $9,199 11 payments
  2. INFUSE BONE GRAFT $6,590 6 payments
  3. CD HORIZON $2,589 18 payments
  4. INFUSE Bone Matrix/Graft $2,223 3 payments
  5. Adaptix $2,200 1 payment
  6. MASTERGRAFT $2,200 1 payment
  7. CREO $2,056 4 payments
  8. INFUSE Bone Matrix/Graft $1,100 1 payment
  9. MAGNETOS $706 4 payments
  10. UNID_PASS $666 7 payments
  11. Other $12,731 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $154,301 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

35

Median for Neurosurgery: 83

Drug cost

$225

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 24 $129
Methocarbamol Generic 11 $96

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$246,850

Medicare's payments for the services billed

Medicare patients

148

Average age 73

Services billed

774

81 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 45%
Depression 39%
Ischemic heart disease 38%
Chronic kidney disease 27%
Heart failure 24%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record